Discovering Therapies for Neuromuscular Disorders
Deep Genomics to collaborate with Wave Life Sciences to discover novel therapies for genetic neuromuscular disorders
CAMBRIDGE, Mass. U.S.A. and TORONTO, Ontario, Canada, April 10, 2018 - Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, and Deep Genomics Inc., the leading AI therapeutics company that is building a ...
Taking on Metabolic & Neurodegenerative Disorders
Deep Genomics to identify oligonucleotide candidates for treating genetically defined metabolic and neurodegenerative disorders
For the first time, machine learning will be used at every step of drug discovery to identify candidates for treating genetically defined metabolic and neurodegenerative disorders.
TORONTO, Ontario, Canada, March 26, 2018 - Deep Genomics, the leading AI therapeutics company that has built a platform using ...
$13M Invested in AI Platform for Genetic Medicines
Equity investment by Khosla Ventures, True Ventures and Bloomberg Beta will be used to direct platform to drug discovery
AI platform to unlock new classes of anti-sense oligonucleotide therapies.
TORONTO, Ontario, Canada, September 25, 2017 - Deep Genomics, the leading AI therapeutics company, received a USD $13 million equity investment led by Khosla Ventures, one of the top venture capital firms. They are accompanied by ...